Fig. 2

Western blot analysis for KCC2 and NKCC1 proteins of brain slices in vitro. Western blot analysis for KCC2, NKCC1 at 0.5 μm (A), 1µM (D), 5µM and 10µM (G) of etomidate. Quantification of blot after normalization to α-tubulin of KCC2 (B), NKCC1(C), in control group, 0.5 µM etomidate group, 0.5 µM etomidate plus 100 µM lidocaine group, 0.5 µM etomidate plus 100 µM NMDA group and 0.5 µM etomidate plus 100 µM AP5 group in neocortex and hippocampus (n = 6 rats in each group). Quantification of blot after normalization to α-tubulin of KCC2(E), NKCC1(F) in control group, 1 µM etomidate group, 1 µM etomidate plus 100 µM lidocaine group, 1 µM etomidate plus 100 µM NMDA group and 1 µM etomidate plus 100 µM AP5 group in neocortex and hippocampus (n = 6 rats in each group). Quantification of blot after normalization to α-tubulin of KCC2 (H), NKCC1 (I) in control and 5 µM and 10 µM etomidate groups (n = 6 rats in each group). Con: Control. Eto: Etomidate. Pro: Propofol. Lido: Lidocaine. AP5: DL-2-amino-5-phosphopentanoic acid. NMDA: N-methyl-d-aspartate.*: p < 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001 by one-way multiple comparisons ANOVA and two-tailed t-Test